Oncology

News

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the res

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petosemtamab in he

News

Amgen adds BiTE to its cancer range as FDA clears Imdelltra

Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority revie

News

AI-powered WhatsApp messaging cleared for NHS pilot

An artificial intelligence-driven WhatsApp messaging platform for scheduling cervical cancer screening appointments is being piloted in London to see if it can improve tak

News

FDA clears BMS’ Breyanzi for follicular lymphoma

Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

ASCO: AffyImmune claims a first with CAR-T for solid tumours

ASCO: Merus bispecific garners attention after abstract drop

Amgen adds BiTE to its cancer range as FDA clears Imdelltra

AI-powered WhatsApp messaging cleared for NHS pilot

FDA clears BMS’ Breyanzi for follicular lymphoma

US launches probe of German 'underpayment' for medicines

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks